Avosentan

Overview

Avosentan (Ro 67-0565; SPP-301) is an orally active endothelin ( ETA ) receptor antagonist. Avosentan can block the ETA receptor, thereby reducing vascular contraction and exerting a renal protective effect. Avosentan inhibits vascular contraction caused by ET-1 and alleviates the reduction in retinal and optic nerve head blood flow induced by it, lowering intraocular pressure in the glaucoma monkey model. Avosentan non-specifically blocks ETB receptors at high doses, inhibiting ETB-mediated diuresis and natriuresis, and may cause fluid retention. Avosentan can be used to reduce proteinuria with diabetic nephropathy, but induces significant fluid overload and congestive heart failure.

Application

Products | Products > Disease Areas > Pain | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Hypertension | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Cardiovascular Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Endocrinology | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Endothelin Receptor

Product Information

• Catalog No.: HY-15195
• CAS No.: 290815-26-8
• Molecular Formula: C23H21N5O5S
• Molecular Weight: 479.51
• Purity: 98.15%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 0.67 mg/mL (1.40 mM); Clear solution
• Availability: In-stock

Source

Original product source